European Equity Partners
Venture capitalInactiveGuernsey · Seed–Growth · 3 people tracked
This fund appears to be inactive.
UK Companies House records show EUROPEAN EQUITY PARTNERS LIMITED (no. 04919487) as dissolved. It is unlikely to be making new investments — this profile is kept for reference and historical accuracy.
Investment thesis
EEP invests in life sciences companies aiming to build best-in-class technologies and business organisations with the potential to become global leaders in their field. Drawing on more than 25 years of sector experience, deep specialist knowledge and an established network, the firm backs early-stage growth companies and works closely with founders and management to help them realise their potential. As a privately owned investment company, EEP makes a limited number of highly selective investments and commits fully to each, providing dedication and hands-on engagement alongside capital.
Source: firm website, verified Aug 3, 2026.
Team · 3 people
from the firm's website & public directories
What they invest in
from 5 of 17 portfolio companiesBiotech ×4Hardware ×2Medical Devices ×2AdTech ×1Advanced Manufacturing ×1AgTech ×1AI & Machine Learning ×1Cloud Computing ×1
HQs:United States×1
Investments · 17 tracked
founders shown can be your intro pathAGC Biologics is a global contract development and manufacturing organization (CDMO) providing development and cGMP manufacturing services for protein-based biologics and advanced therapies, including mammalian and microbial biologics, cell therapies, viral vectors, mRNA, and plasmid DNA.
Advanced ManufacturingBiotechMedical Devices
European multi-service life sciences CRO focused on early clinical development and bio-analysis, now rebranded as SGS Life Sciences.
Specialty pharma company focused on women's health and addiction medicine; acquired by Norgine in 2020.
Pre-clinical research organization offering drug development services, now part of Charles River Laboratories.
International biopharmaceutical CDMO (now rebranded as AGC Biologics) serving API and cell and gene therapy manufacturing; EEP invested 2002, sold to AGC in 2017.
Alphabet Inc. is a holding company that oversees a portfolio of businesses including Google, which provides internet search, advertising, and related services; cloud infrastructure; and productivity software.
AdTechAI & Machine LearningCloud Computing
Larry Page(CEO of Alphabet)Sergey Brin(President of Alphabet)
Integrated optical network transport
Sunnyvale, US
Thomas J. Fallon(Executive Officer, Director)Bob Jandro(Executive Officer)James L. Laufman(Executive Officer)Mark A. Wegleitner(Director)Rajal M. Patel(Director)David W. Heard(Executive Officer)
Baltimore-based CRO providing pharmacology and bioanalysis to the generic pharmaceutical industry; sold to Bioanalytical Systems Inc. in 2002.
Corporate subscription management provider offering integrated administration of print and online information; sold via secondary MBO in 2012.
Optical networking solutions provider using CWDM/DWDM technology; IPO'd on NASDAQ OMX Stockholm in 2011 and later acquired by Infinera.
French designer and manufacturer of purification processing equipment for biologics API, viral vectors, mRNA, lipid nanoparticles, exosomes and vaccines.
Verdot Biotechnologies manufactures chromatography columns, chromatography systems, and tangential flow filtration systems used in the purification of biopharmaceuticals such as advanced therapies, mRNA therapeutics, antibodies, recombinant proteins, and vaccines.
BiotechHardwareMedical Devices
Multi-platform publishing business specialising in time and location specific leisure and events content; sold to John Wiley & Sons in 2006, now part of Alphabet.
Exits · 2
IPOs and acquisitions across the tracked portfolioAzantaacq. by NorgineTransmodeacq. by Infinera
Portfolio news
latest coverage across their companiesPrincipals & officers · per Companies House
what is this? ⓘCorporate secretary · since 2003
Director · British · since 2003
Roderick Bruce Crawford — 75–100% of shares
Frequently asked questions
- What stage does European Equity Partners invest at?
- European Equity Partners invests at the Seed, Series A, Series B, Growth stages.
- What is European Equity Partners's typical check size?
- European Equity Partners typically writes checks of $540K – $10.8M.
- What sectors does European Equity Partners focus on?
- European Equity Partners focuses on Biotech, Deep Tech, Healthtech, Medical Devices.
- Where is European Equity Partners located?
- European Equity Partners is headquartered in Guernsey, GG.
- Does European Equity Partners lead rounds?
- Yes, European Equity Partners leads investment rounds.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.